CAN
MYGN icon

Cetera Advisor Networks’s Myriad Genetics MYGN Stock Holding History

Cetera Advisor Networks’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-787
Closed -$9K – 2359
2020
Q2 		$9K Buy
+787
New +$11.2K ﹤0.01% 2760

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cetera Advisor Networks's MYGN Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Myriad Genetics (MYGN) in Q3 2020, closing a stake of 787 shares — an estimated $9K sold.

Cetera Advisor Networks first reported a position in MYGN in Q2 2020 and held it in 1 quarter. The position peaked at $9K in Q2 2020. 192 funds tracked by Wall St. Rank hold MYGN as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Myriad Genetics position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 787 Myriad Genetics shares in Q3 2020, an estimated $9K.
  • Cetera Advisor Networks first reported a position in Myriad Genetics in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Myriad Genetics position peaked at $9K in Q2 2020.
  • 192 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.